Genus PLC
LSE:GNS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genus PLC
Revenue
Genus PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Genus PLC
LSE:GNS
|
Revenue
£672m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
6%
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Revenue
$72.6m
|
CAGR 3-Years
71%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Revenue
£400m
|
CAGR 3-Years
41%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Revenue
£168.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
14%
|
CAGR 10-Years
27%
|
|
|
Niox Group PLC
LSE:NIOX
|
Revenue
£48.7m
|
CAGR 3-Years
16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
16%
|
|
Genus PLC
Glance View
Amidst the rolling countryside of Britain, Genus PLC has quietly but profoundly reshaped the agricultural landscape since its formation. With roots tracing back to the British government's Milk Marketing Board, Genus blossomed into an influential player at the intersection of biotechnology and farming. This was not by chance, but through a strategic evolution into a global pioneer in animal genetics. At the heart of their operations, Genus enhances animal breeding by leveraging cutting-edge science, particularly the technology of selective breeding and genetics. They focus primarily on two types of livestock: bovine (cattle) and porcine (pigs), catering to agricultural sectors worldwide. Essentially, through their subsidiaries—ABS Global, focusing on cattle, and PIC, specializing in pigs—the company maximizes genetic improvements, aiding farmers in producing leaner, more disease-resistant, and ultimately more productive livestock. The business model of Genus PLC revolves around the intricate science of animal genetics and the commercial viability it crafts from this foundation. By developing genetically superior livestock, they provide a distinct competitive advantage to farmers who seek more yield with less resource input. The company harnesses sophisticated techniques like genomics and advanced biotechnologies, including gene editing, to achieve these outcomes. With each genetic line licensed, Genus receives a license fee, ensuring a steady stream of revenue. Additionally, sales channels are bolstered by continuous consultative partnerships with farmers to enhance productivity, cementing a cycle of value that perpetuates mutual growth. By marrying science with agricultural prosperity, Genus PLC remains a vanguard in a field where innovation is as essential as the soil itself.
See Also
What is Genus PLC's Revenue?
Revenue
672m
GBP
Based on the financial report for Dec 31, 2025, Genus PLC's Revenue amounts to 672m GBP.
What is Genus PLC's Revenue growth rate?
Revenue CAGR 10Y
6%
Over the last year, the Revenue growth was 0%.